Speakers

Sophie Kirschner is Associate Director of Translational Medicine Genomics at AstraZeneca Oncology R&D in Cambridge, UK. She leads genomic strategies for early-phase clinical trials, focusing on next-generation sequencing and biomarker development to enable precision medicine. Sophie’s research background includes a postdoctoral fellowship at the Ludwig Institute for Cancer Research, University of Oxford, where she studied epigenetic mechanisms in cancer. She holds a PhD in Epigenetics and Immunology from the University of Trier and has authored multiple peer-reviewed publications, including recent work on BRCA1 and RAD51C promoter hypermethylation (Journal of Molecular Diagnostics, 2024). She is the recipient of AstraZeneca’s 2024 Science Catalyst R&D Innovation Award. Sophie is committed to advancing translational epigenomics to accelerate the delivery of innovative cancer therapies to patients worldwide.